Gastric Cancer
Copyright ©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Apr 14, 2007; 13(14): 2044-2047
Published online Apr 14, 2007. doi: 10.3748/wjg.v13.i14.2044
Table 5 Change of VEGF protein in supernatant (mean ± SD, n = 3)
GroupVEGF (p/ng per L)Inhibition efficiency (%)
Normal control group414.0 ± 61.5-
Lipofectin group366.3 ± 25.5-
siRNASCR group350.0 ± 25.74.46
siRNA1 group164.6 ± 22.7b55.1
siRNA2 group166.3 ± 26.6b54.6